Delving into the Latest Updates on University Of Insurbia with Synapse

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

治疗性疫苗	1

关联

1

项与 University Of Insurbia 相关的药物

IMA-970A

靶点-

作用机制

免疫刺激剂

在研机构

CureVac SE [+4]

原研机构

Fondazione Irccs Istituto Nazionale Dei Tumori

在研适应症

肝细胞癌

非在研适应症-

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

100 项与 University Of Insurbia 相关的临床结果

登录后查看更多信息

0 项与 University Of Insurbia 相关的专利（医药）

登录后查看更多信息

8

项与 University Of Insurbia 相关的文献（医药）

2023-01-01·Pathology oncology research : POR

Influence of the microbiota on the effectiveness and toxicity of oncological therapies, with a focus on chemotherapy.

Review

作者: Palazzi, Chiara Maria ; Bertuccioli, Alexander ; Di Pierro, Francesco ; Cardinali, Marco ; Zonzini, Giordano Bruno ; Cazzaniga, Massimiliano

Recent studies have highlighted a possible correlation between microbiota composition and the pathogenesis of various oncological diseases. Also, many bacterial groups are now directly or indirectly associated with the capability of stimulating or inhibiting carcinogenic pathways. However, little is known about the importance and impact of microbiota patterns related to the efficacy and toxicity of cancer treatments. We have recently begun to understand how oncological therapies and the microbiota are closely interconnected and could influence each other. Chemotherapy effectiveness, for example, appears to be strongly influenced by the presence of some microorganisms capable of modulating the pharmacokinetics and pharmacodynamics of the compounds used, thus varying the real response and therefore the efficacy of the oncological treatment. Similarly, chemotherapeutic agents can modulate the microbiota with variations that could facilitate or avoid the onset of important side effects. This finding has or could have considerable relevance as it is possible that our ability to modulate and modify the microbial structure before, during, and after treatment could influence all the clinical parameters related to pharmacological treatments and, eventually, the prognosis of the disease.

2021-02-01·Journal of Thoracic Disease4区 · 医学

Right ventricular failure after left ventricular assist device implantation: a review of the literature

4区 · 医学

Review

作者: Chiarini, Giovanni ; De Piero, Maria Elena ; Lo Coco, Valeria ; Raffa, Giuseppe M ; Maessen, Jos ; Lorusso, Roberto ; Massimi, Giulio ; Kowalewski, Mariusz

Right ventricular failure (RVF) following left ventricular assist device (LVAD) implantation remains a major complication which may significantly impair patient outcome. The genesis of RVF is, however, multifactorial, and the mechanisms underlying such a condition have not been fully elucidated, making its prevention challenging and the course not always predictable. Although preoperative risks factors can be associated with RV impairment, the physiologic changes after the LV support, can still hamper the function of the RV. Current medical treatment options are limited and sometimes, patients with a severe post-LVAD RVF may be unresponsive to pharmacological therapy and require more aggressive treatment, such as temporary RV support. We retrieved 11 publications which we assessed and divided in groups based on the RV support [extracorporeal membrane oxygenation (ECMO), right ventricular assist device (RVAD), TandemHeart with ProtekDuo cannula]. The current review comprehensively summarizes the main studies of the literature with particular attention to the RV physiology and its changes after the LVAD implantation, the predictors and prognostic score as well as the different modalities of temporary mechanical cardio-circulatory support, and its effects on patient prognosis for RVF in such a setting. In addition, it provides a decision making of the pre-, intra and post-operative management in high- and moderate- risk patients.

2005-11-16·Blood

Use of Low Dose Oral Vitamin K in the Treatment of Patients with INR Values of More Than 10.0.

作者: Selby, Rita ; Kearon, Clive ; Blostein, Mark ; Crowther, Mark A. ; Ginsberg, Jeff S. ; Kahn, Susan R. ; Schulman, Sam ; Anderson, David ; Garcia, David ; Kovacs, Michael J. ; Wells, Phil ; Witt, Daniel M. ; Wang, Luqi ; Ageno, Walter

AbstractThe optimal therapy for patients who present with markedly prolonged INR values during warfarin therapy is undefined. Evidence suggests that the risk of bleeding increases directly with the degree of prolongation of the INR. Traditional therapy for patients with excessive warfarin associated anticoagulation has included warfarin withdrawal with or without vitamin K, transfusion therapy and admission to the hospital. As part of an ongoing international study, we prospectively enrolled 32 consecutive warfarin-treated patients presenting with an INR of more than 10.0. Eligible patients had no evidence of active bleeding or need for immediate correction of their INR. All patients received 2.5 mg of oral vitamin K, were not treated with coagulation factor replacement, and were followed over 90 days for clinical events and their INR response. Seventeen of the 32 patients were women, with an average age of 65.8 (range 31 to 89). Treatment of venous thrombosis and atrial fibrillation (12 patients each) were the most common indications for warfarin. Twenty-five patients had a target INR of 2.0 to 3.0; the remainder had a target of 2.5 to 3.5. The mean INR at presentation was 12.9 (range 10.0 to 21.2). Of the 25 patients with a recorded INR value on the day following vitamin K, 19 (76%) had an INR of 6.0 or less (range 1.6 to 17.5, mean 5.0, 2 less than 2.0). On day 7 after study drug, the mean INR was 3.5 (range 1.6 to 17.5). Six (19%) patients reported bleeding over the 90 days after study drug: 1 (3%) bleed was major (retroperitoneal hemorrhage diagnosed the day after study drug) and 3 patients reported epistaxis or bruising within three days of study drug. Two patients reported late bleeding; one had a fall on day 8 at which time the INR was 10.5, and the other had bleeding associated with a surgical procedure 25 days after study drug. No patients had suspected or confirmed thrombosis, and no patients died during follow-up. This the first prospective study of vitamin K monotherapy for patients with INR values above 10, and confirms prior retrospective analyses which suggest that low dose oral vitamin K effectively lowers the INR in such patients. Our preliminary results also suggest that coagulation factor replacement may be unneeded in such patients. The true risk of bleeding, and the impact of degree of prolongation of the INR on the vitamin K response, will require additional patient recruitment.

100 项与 University Of Insurbia 相关的药物交易

登录后查看更多信息

100 项与 University Of Insurbia 相关的转化医学

登录后查看更多信息